| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6034239 | TAKEDA PHARMS USA | Tricyclic compounds, their production and use |
Jul, 2019
(4 years ago) | |
| US10098866 | TAKEDA PHARMS USA | Pharmaceutical preparation containing copolyvidone |
Nov, 2021
(2 years ago) | |
Rozerem is owned by Takeda Pharms Usa.
Rozerem contains Ramelteon.
Rozerem has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Rozerem are:
- US6034239
- US10098866
Rozerem was authorised for market use on 22 July, 2005.
Rozerem is available in tablet;oral dosage forms.
Rozerem can be used as method of treating a biological rhythm disorder, such as insomnia, method of treating insomnia characterized by difficulty with sleep onset.
The generics of Rozerem are possible to be released after 16 November, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-82) | Oct 20, 2011 |
Drugs and Companies using RAMELTEON ingredient
Market Authorisation Date: 22 July, 2005
Treatment: Method of treating insomnia characterized by difficulty with sleep onset; Method of treating a biological rhythm disorder, such as insomnia
Dosage: TABLET;ORAL
ROZEREM family patents
